Formulation Development
Avalo Therapeutics Transfers Anti-IL-18 Antibody to Apollo Therapeutics
Avalo Therapeutics, Inc. and Apollo Therapeutics Group Limited have entered into a worldwide, exclusive license agreement granting rights to Apollo to research, develop, manufacture and commercialize….
CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients With Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. recently announced the completion of enrollment for RESPONSE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary….
Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates
Vaxxinity, Inc. recently presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau protein for Alzheimer’s disease (AD) during a poster session at the….
Akari Therapeutics Narrows Pipeline Focus
Akari Therapeutics, Plc recently announced it is prioritizing two pipeline programs. Cash and resources will be reallocated to the Phase 3 clinical trial of nomacopan…
Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 in Advanced Solid Tumors
Agenus Inc. recently announced the first patient has been dosed in the Phase 1 study of AGEN1571 in advanced solid tumors. The dose-escalation and expansion…
SciSparc Signs Clinical Trial Agreement With Yale University to Conduct Phase 2b Trial in Tourette Syndrome
SciSparc Ltd. recently announced the addition of another site of excellence, the Yale Child Study Center at Yale University, to its Phase 2b clinical trial…
Nanoform & Pharmanovia to Breathe New Life Into Iconic Medicines
Nanoform Finland Plc. recently announced it has partnered with Pharmanovia, a fast-growing specialty pharma business with a portfolio of over 20 branded drugs in 140 markets…..
TFF Pharmaceuticals Expands R&D Operations With New Austin Facility
TFF Pharmaceuticals, Inc. recently announced a significant expansion of its R&D operations through the lease of a new research and development facility located in Austin,…
US Alliance Pharma Acquires UK-Based LGC’s Drug Development Solutions Business
Alliance Pharma recently closed on the purchase of Drug Development Solutions (DDS) from LGC. Ampersand Capital Partners, a global healthcare private equity firm, and KKR & Co. Inc., a leading global investment….
Comera Life Sciences Announces Favorable Preclinical Topline Safety Results of Lead SQore Excipient
Comera Life Sciences Holdings, Inc. recently announced favorable topline results from its recently completed SEQURUS-1 study. The results of this preclinical study provide supportive evidence…
Evonik Now Offers Enteric-Protected Ready-to-Fill Capsules – EUDRACAP- in IPEC-GMP Quality
Evonik’s EUDRACAP enteric easy-to-handle capsules are now globally available produced under IPEC-GMP. Launched last year, EUDRACAP enteric are….
Roquette Expands PEARLITOL SD Mannitol Range for Highly Sensitive APIs
Roquette recently announced the addition of a new grade to its PEARLITOL SD mannitol range for direct compression – PEARLITOL 150 SD. Developed specifically for….
ABL Partners With KaliVir Immunotherapeutics to Advance Development of Oncolytic Viruses
ABL recently announced its partnership with KaliVir Immunotherapeutics in which ABL will manufacture KaliVir’s oncolytic viruses for its….
Immunocore Announces Dosing of First Patient With ImmTAV Bispecific for HIV
Immunocore Holdings plc recently announced the dosing of the first patient in the first-in-human Phase 1 clinical trial of IMC-M113V, a new class of bispecific…
MediWound Announces Positive Initial Data From Phase 1/2 Study for the Treatment of Basal Cell Carcinoma
MediWound Ltd. recently announced positive initial data from 11 patients in its ongoing open-label Phase 1/2 study of MW005 for the treatment of low-risk Basal…
2022 Respiratory Drug Development eBook - Demand Accelerates Devices
This fourth annual Drug Development & Delivery Respiratory eBook highlights the pMDI development path, as well as the importance of a holistic approach to that development that includes the patient and all stakeholders across the product’s life cycle.
Acer Therapeutics & Relief Therapeutics Announce China National Intellectual Property Administration Issued Utility Model Patent
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics recently announced the China National Intellectual Property Administration (CNIPA) issued Electronic Patent Certificate ZL202122004991.9 on May…
Sirio Pharma Announces Agreement to Acquire Best Formulations
Sirio Pharma Co., Ltd. – the global nutraceutical contract development and manufacturing organization (CDMO) – and Best Formulations, Inc. recently announced that they have entered…
Absci Enters Multi-Program Collaboration With Emerging Biotech Partner
Absci Corporation recently announced it has entered into a collaboration agreement with an undisclosed biotech partner. The partner is a stealth-mode company, led by….
Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase 3 Part A Clinical Trial
Akari Therapeutics, Plc recently announced a patient has completed the course of investigational nomacopan treatment in the open-label, multi-center Phase 3 Part A clinical trial in pediatric hematopoietic stem….
